The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Masafumi Ikeda
No relevant relationships to disclose
Akihiro Sato
No relevant relationships to disclose
Nobuo Mochizuki
No relevant relationships to disclose
Kayo Toyosaki
No relevant relationships to disclose
Chika Miyoshi
No relevant relationships to disclose
Rumi Fujioka
No relevant relationships to disclose
Shuichi Mitsunaga
No relevant relationships to disclose
Satoshi Shimizu
No relevant relationships to disclose
Izumi Ohno
No relevant relationships to disclose
Hideaki Takahashi
No relevant relationships to disclose
Hiroyuki Okuyama
No relevant relationships to disclose
Hiromi Hasegawa
No relevant relationships to disclose
Shogo Nomura
No relevant relationships to disclose
Toshiki Ohkubo
No relevant relationships to disclose
Satoshi Yomoda
No relevant relationships to disclose
Satoshi Kishino
No relevant relationships to disclose
Hiroyasu Esumi
No relevant relationships to disclose